ArticleAsia Oceania journal of nuclear medicine & biology2015
Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System.
Article in Asia Oceania journal of nuclear medicine & biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 21 citations in OpenAlex.
- Automated Synthesis of Radiopharmaceuticals: Technology, Applications, and Regulatory Perspectives.Nuclear medicine and molecular imaging · 2026Review
- A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents.Nature protocols · 2026Article
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Multifactorial analysis of radiochemical purity in high-activityEJNMMI radiopharmacy and chemistry · 2025Article
- Somatostatin Receptor-Directed Theranostics in Esthesioneuroblastoma.Clinical nuclear medicine · 2025Article
- Lead-it-EAZY! GMP-compliant production of [EJNMMI radiopharmacy and chemistry · 2024Article
- Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Radioligand Therapy with [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.Journal of cancer research and clinical oncology · 2023Article
- A High Separation Factor forMolecules (Basel, Switzerland) · 2021Article
- Ac-EAZY! Towards GMP-Compliant Module Syntheses ofPharmaceuticals (Basel, Switzerland) · 2021Article
- A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies withMolecules (Basel, Switzerland) · 2020Review
- LutatheraPharmaceuticals (Basel, Switzerland) · 2019Review
- A Comparison of 2D and 3D Kidney Absorbed Dose Measures in Patients ReceivingAsia Oceania journal of nuclear medicine & biology · 2018Article
- In Vivo Measurement and Characterization of a Novel Formulation of [Asia Oceania journal of nuclear medicine & biology · 2016Article
- In vivo quantification of (177)Lu with planar whole-body and SPECT/CT gamma camera imaging.EJNMMI physics · 2015Article
- Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer.Nuclear medicine and biologyArticle
- Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis ofIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPeptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 ((90)Y) and lutetium-177 ((177)Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy. In-house production with automated PRRT synthesis systems have clear advantages over manual methods resulting in increasing use in hospital-based radiopharmacies. We report on our one year experience with an automated radiopharmaceutical synthesis system.
methodsAll syntheses were carried out using the Eckert & Ziegler Eurotope's Modular-Lab Pharm Tracer® automated synthesis system. All materials and methods used were followed as instructed by the manufacturer of the system (Eckert & Ziegler Eurotope, Berlin, Germany). Sterile, GMP-certified, no-carrier added (NCA) (177)Lu was used with GMP-certified peptide. An audit trail was also produced and saved by the system. The quality of the final product was assessed after each synthesis by ITLC-SG and HPLC methods.
resultsA total of 17 [(177)Lu]-DOTATATE syntheses were performed between August 2013 and December 2014. The amount of radioactive [(177)Lu]-DOTATATE produced by each synthesis varied between 10-40 GBq and was dependant on the number of patients being treated on a given day. Thirteen individuals received a total of 37 individual treatment administrations in this period. There were no issues and failures with the system or the synthesis cassettes. The average radiochemical purity as determined by ITLC was above 99% (99.8 ± 0.05%) and the average radiochemical purity as determined by HPLC technique was above 97% (97.3 ± 1.5%) for this period.
conclusionsThe automated synthesis of [(177)Lu]-DOTATATE using Eckert & Ziegler Eurotope's Modular-Lab Pharm Tracer® system is a robust, convenient and high yield approach to the radiolabelling of DOTATATE peptide benefiting from the use of NCA (177)Lu and almost negligible radiation exposure of the operators.
Indexed as
Identifiers
27408890PMC4937639W1226786859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.